Inhibikase Therapeutics, Inc. Common Stock
IKTInhibikase Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing kinase inhibitors for the treatment of neurodegenerative and infectious diseases. The company's approach involves targeting aberrant kinase activity involved in disease progression, aiming to create therapies with improved safety and efficacy profiles. Founded with an emphasis on precision medicine, Inhibikase leverages its expertise in kinase biology to advance novel therapeutic candidates.
Company News
Inhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.
A Polish credit bureau analysis reveals that including Buy Now Pay Later (BNPL) transaction data in credit histories could help nearly 40% of 'thin-file' bank customers improve their creditworthiness, with BNPL transactions showing high repayment rates and low default risks.
The article discusses 10 small-cap stocks that could outperform in 2025, citing factors like falling interest rates, low valuations, and potential shifts in industrial production.
Company expects to report trial results in 4Q24 Company expects to report trial results in 4Q24
- Company positioning multiple assets for late-stage development across its therapeutic pipeline –
